Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

MASSACHUSETTS GENERAL HOSPITAL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1811-01-01

Employees: -

Market Cap: -

Website: http://www.massgeneral.org/international

Clinical Trials

Effect of Nitric Oxide in Cardiac Surgery Patients With Endothelial Dysfunction.

Phase 3

Active, not recruiting

Conditions: Acute Kidney Injury

Interventions: Other: Placebo
Drug: Nitric Oxide

First Posted Date: 2016-07-19

Last Posted Date: 2022-11-10

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 250

Registration Number: NCT02836899

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

A Study of Denosumab in Multiple Myeloma Patients with Renal Insufficiency

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Denosumab Q4W

First Posted Date: 2016-07-14

Last Posted Date: 2024-12-30

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 55

Registration Number: NCT02833610

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸
Massachusetts general Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 4 locations

Prospective Evaluation of Infants With Spinal Muscular Atrophy:

Conditions: Spinal Muscular Atrophy

First Posted Date: 2016-07-13

Last Posted Date: 2020-09-02

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 1000

Registration Number: NCT02831296

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

Phase 2

Completed

Conditions: Neurofibromatosis 2
Meningioma

Interventions: Drug: AZD2014

First Posted Date: 2016-07-13

Last Posted Date: 2022-06-13

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 18

Registration Number: NCT02831257

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer

Phase 1

Active, not recruiting

Conditions: Breast Cancer

Interventions: Biological: PVX-410
Biological: Durvalumab
Drug: Hiltonol

First Posted Date: 2016-07-11

Last Posted Date: 2023-11-14

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 22

Registration Number: NCT02826434

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States
🇺🇸
Massachusetts general Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 2 locations

Effectiveness of Light for Enhancement of Cognition by Transcranial Repeated Application (ELECTRA)

Not Applicable

Completed

Conditions: Disease Type and/or Category Not Applicable

Interventions: Device: Omnilux

First Posted Date: 2016-06-29

Last Posted Date: 2019-09-18

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 80

Registration Number: NCT02817061

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Repurposing Dexmedetomidine as an Orally Administered Sleep Therapeutic

Phase 1

Completed

Conditions: Sleep
Insomnia

Interventions: Drug: Dexmedetomidine
Other: Saline Placebo

First Posted Date: 2016-06-29

Last Posted Date: 2019-10-02

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 15

Registration Number: NCT02818569

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors

Phase 1

Withdrawn

Conditions: Keratosis, Actinic
Keratosis
Skin Neoplasms

Interventions: Other: Sugar Pill
Drug: Heliocare with Fernblock PLE technology

First Posted Date: 2016-06-27

Last Posted Date: 2019-03-08

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT02813902

Implementation of a Population Health Chronic Disease Management Program

Completed

Conditions: Cardiovascular Diseases
Hypertension
Diabetes Mellitus

Interventions: Other: Centralized support for population health management activities

First Posted Date: 2016-06-24

Last Posted Date: 2016-06-24

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 108000

Registration Number: NCT02812303

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma

Phase 2

Terminated

Conditions: Non-Hodgkin Lymphoma

Interventions: Drug: Blinatumomab

First Posted Date: 2016-06-23

Last Posted Date: 2025-05-23

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 13

Registration Number: NCT02811679

Locations: 🇺🇸
Massachusetts general Hospital, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy